Elevation of Cardiac Biomarkers in COVID-19 As a Major Determinant for Mortality: A Systematic Review

Tracy Anabella Hermansyah, Eka Ginanjar, Valerie Hirsy Putri


Background: This study aimed to summarize the prognosis of Corona Virus Disease 2019 (COVID-19) patients with elevated troponin and N-terminal pro brain natriuretic peptide (NT-proBNP) levels and demonstrate the involvement of myocardial injury as a complication in COVID-19. Methods: A systematic literature search was performed using several databases (PubMed, MEDLINE, PROQUEST and SCOPUS ) for studies published up to August 2020. Observational studies about the mortality outcome of COVID-19 patients who experienced cardiac injury, as defined by the elevation of serum levels of troponin, brain natriuretic peptide (BNP), with NT-proBNP or only BNP or only NT-proBNP, were included. In addition, a critical appraisal was conducted for all included studies using the Critical Appraisal for Prognostic Studies checklist published by the Centre for Evidence-Based Medicine by the University of Oxford. Results: Seven retrospective observational studies fulfilled the inclusion criteria. This study found that there is a higher risk of death in COVID 19 patients with higher levels of troponin and NT-proBNP, indicating the importance of these biomarkers as determinant factors to predict in-hospital deaths. Conclusion: Based on the analysis, elevation of troponin  and NT-proBNP levels plays an essential role in determining the patient prognosis because it is shown to be associated with in-hospital mortality. This also supports the involvement of myocardial injury as a prominent fatal complication in COVID-19.


COVID-19; myocardial injury; troponin; BNP; NT-proBNP; prognostic factors


Atri D, Siddiqi HK, Lang J, Nauffal V, Morrow DA, Bohula EA. COVID-19 for the Cardiologist: A current review of the virology, clinical epidemiology, cardiac and other clinical manifestations and potential therapeutic strategies. JACC: Basic to Translational Science. 2020. doi: https://doi.org/10.1016/j.jacbts.2020.04.002.

Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55(4):2000607. Published 2020 Apr 16. doi:10.1183/13993003.00607-2020

WHO. Coronavirus disease 2019 (COVID-19) Situation Report – 97. Geneva, Switzerland. WHO; 2020. Accessed at 26/04/2020. Cited from https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200426-sitrep-97-COVID-19.pdf?sfvrsn=d1c3e800_6

Zeng JH, Liu YX, Yuan J, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights [published online ahead of print, 2020 Apr 10]. Infection. 2020;1-5. doi:10.1007/s15010-020-01424-5

Rizzo P, Vieceli Dalla Sega F, Fortini F, Marracino L, Rapezzi C, Ferrari R. COVID-19 in the heart and the lungs: could we «Notch» the inflammatory storm?. Basic Res Cardiol. 2020;115(3):31. Published 2020 Apr 9. doi:10.1007/s00395-020-0791-5

Zheng Y., Ma Y., Zhang J, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17:259–60 (2020). https://doi.org/10.1038/s41569-020-0360-5

Hua A, O’Gallagher K, Sado D, Byrne J. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19 [published online ahead of print, 2020 Mar 30]. Eur Heart J. 2020;ehaa253. doi:10.1093/eurheartj/ehaa253

Hu H, Ma F,Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin, European Heart Journal. 2020, ehaa190. https://doi.org/10.1093/eurheartj/ehaa190

Gao et al. Role of Troponin I Proteolysis in the Pathogenesis of Stunned Myocardium. AHA J. 2020;80(3):393-9. https://doi.org/10.1161/01.res.0000435855.49359.47

Sharma S, Jackson PG, Makan J. Cardiac troponins. J Clin Pathol. 2004;57(10):1025-6. doi:10.1136/jcp.2003.015420

Babapoor-Farrokhran S, Gill D, Walker J, Rasekhi RT, Bozorgnia B, Amanullah A. Myocardial injury and COVID-19: Possible mechanisms. Life Sci. 2020;253:117723. doi:10.1016/j.lfs.2020.117723

Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease [published online ahead of print, 2020 Mar 21]. Circulation. 2020;10.1161/CIRCULATIONAHA.120.046941.

Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. doi:10.1371/journal.pmed.1000100

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020;395(10229):1038] [published correction appears in Lancet. 2020 Mar

Chen Tao, Wu Di, Chen Huilong, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020; 368

Stefanini, et al. Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. Heart. 2020;106:1512–8.

Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with Coronavirus Disease 2019 (COVID-19) [published online ahead of print, 2020 Mar 27]. JAMA Cardiol. 2020;e201017. doi:10.1001/jamacardio.2020.1017

Gao L., Jiang D., Wen X, et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res. 2020;21:83. https://doi.org/10.1186/s12931-020-01352-w

Zhang, et al. Myocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan, China: A single center retrospective cohort study

Preprint medRxiv. 2020. doi: https://doi.org/10.1101/2020.03.21.20040121.

Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. Published online March 25, 2020. doi:10.1001/jamacardio.2020.0950

Full Text: PDF


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.